Home / Clinical Guideline Hubs / Chapter 5.4
Section 5 — General NICU Care / Supportive Care Verify against local policy v1.0 · July 2026 Baylor Ed. 33 cross-checked Sept 2026

Chapter 5.4 — Neonatal Opioid Withdrawal (NAS / NOWS)

Non-pharmacological (Eat-Sleep-Console) first, rooming-in and breastfeeding support, and stepwise pharmacological treatment — built on West Midlands Neonatal Guidelines 2025–28 and AAP guidance on neonatal opioid withdrawal

Educational guideline — verify locally. Pharmacological treatment (morphine/opioid, adjuncts) and weaning schedules must be verified against the Neonatal Formulary and local policy. Also covers non-opioid withdrawal. Does not replace attending judgment.
BEDSIDE ACTION BOX

1. Overview

Overview

Neonatal abstinence syndrome (NAS) — increasingly termed neonatal opioid withdrawal syndrome (NOWS) when opioids are the cause — is a constellation of withdrawal signs in infants exposed in utero to opioids (and sometimes other substances). Care has shifted decisively toward a non-pharmacological-first, function-based model (Eat, Sleep, Console), keeping mother and baby together, which reduces medication use and hospital stay. Pharmacological treatment is reserved for infants who remain unable to feed, settle, or be consoled despite optimized non-pharmacological care.

Why This Topic Matters

The function-based ESC model markedly reduces opioid treatment and length of stay compared with score-driven care, while supporting maternal–infant bonding. Compassionate, non-judgmental, family-centered care improves outcomes and engagement.

2. Who This Guideline Applies To

Scope
  • Infants with prenatal opioid exposure (or other substances causing withdrawal) and iatrogenic opioid/sedative withdrawal after prolonged NICU sedation (see 5.3).
  • Families needing support, safeguarding, and follow-up.
  • Cross-references: pain/sedation (5.3), developmental care (5.1), and discharge/follow-up (2.5).

3. Key Definitions

TermDefinition
NASNeonatal abstinence syndrome — withdrawal from in-utero substance exposure.
NOWSNeonatal opioid withdrawal syndrome — NAS specifically due to opioids.
Eat, Sleep, Console (ESC)A function-based assessment/care model: is the infant feeding, sleeping, and consolable?
Finnegan scoreTraditional symptom-based scoring tool (less favored than ESC in current practice).
Rooming-inKeeping mother and baby together to support consoling and bonding.

4. Presentation

Signs of Withdrawal
  • CNS: irritability, high-pitched cry, tremors, increased tone, hyperreflexia, difficulty settling, disturbed sleep; seizures (uncommon, severe).
  • GI: poor/uncoordinated feeding, vomiting, loose stools, poor weight gain, excoriation.
  • Autonomic: sweating, sneezing, yawning, nasal stuffiness, mottling, temperature instability.
  • Onset/timing depends on the substance (e.g., short-acting opioids earlier; methadone/buprenorphine later) — observe for an appropriate period.

5. Assessment

Function-Based (ESC)
  • Ask three functional questions: can the infant Eat adequately, Sleep ≥1 hour undisturbed, and be Consoled within a reasonable time?
  • If any domain is failing despite optimized non-pharmacological care, escalate care (and consider pharmacological treatment).
  • Confirm the exposure history (maternal drugs, opioid-agonist treatment, polysubstance) and consider toxicology per local policy and consent.
  • Observe for an appropriate monitoring period based on the substance's half-life before discharge.

6. Non-Pharmacological Care (First-Line)

Optimize Before Any Medication
  • Rooming-in with the parent and maximizing parental presence and consoling.
  • Low-stimulation environment (dim light, quiet), swaddling/containment, skin-to-skin care, and gentle handling.
  • Responsive, frequent feeding; support breastfeeding where appropriate; small frequent feeds; protect sleep.
  • Consistent caregiving and family involvement; treat excoriation and ensure hydration/weight gain.

7. Management Algorithm

1
Identify exposure & keep together
Confirm history; room-in with parent; start non-pharmacological care from the outset.
2
Assess function (ESC)
Can the infant eat, sleep ≥1 h, and be consoled? Optimize non-pharmacological measures for any failing domain.
3
Failing despite optimized care?
Persistent inability to eat/sleep/console or severe signs → start pharmacological treatment (usually oral morphine) per policy.
4
Titrate & add adjunct if needed
Titrate opioid to control; add an adjunct (e.g., clonidine/phenobarbital) per policy for refractory cases or polysubstance exposure.
5
Wean & plan discharge
Wean the opioid gradually once stable; continue non-pharmacological care; arrange follow-up and family/social support.
6
⚠ Do-not-miss
Seizures/severe withdrawal; inadequate feeding/weight loss; concurrent illness (sepsis, hypoglycemia) mimicking withdrawal; and safeguarding needs.

8. Pharmacological Treatment (Verify Doses Locally)

AgentRoleNotes
Oral morphineFirst-line for opioid withdrawal.Titrate to control; wean gradually; monitor for over-sedation/respiratory depression.
ClonidineAdjunct / alternative.Monitor blood pressure/heart rate.
PhenobarbitalAdjunct (esp. polysubstance/non-opioid).Sedation; long half-life; per policy.
Morphine, dose by dose (Baylor Ed. 33 — high certainty evidence, strong recommendation)
  • When to start: three consecutive scores above 8, or an average of 8 or more across three scores, or a single score above 12 once you have excluded a confounding reason for it, or an infant not well managed on Eat-Sleep-Console after non-pharmacological care has been maximized. Scores below 8 mean symptoms are controlled.
  • Start at 0.05 mg/kg/dose orally every 3 hours — consider 1–3 as-needed doses before moving to standing doses.
  • Escalate by 0.03 mg/kg/dose every 3 hours until symptoms are controlled — average scores below 8 over 24 hours, or well managed on ESC.
  • Hold the same dose for at least 48 hours with scores below 8 before weaning.
  • Wean by 10% of the original dose every 24 hours, keeping 10% as the weaning factor for the rest of treatment. Do not weight-adjust the dose and do not change the frequency — keep it every 3 hours, because morphine's half-life is short. Stop when the dose falls below 0.02 mg/kg/dose.
  • Backsliding: two consecutive scores above 8 during weaning — first confirm the non-pharmacological measures are optimized and examine the infant for another cause, then return to the last dose at which they were stable. If scores stay up, weight-adjust or step the dose up until scores are ≤8; once stable for 48 hours, resume the 10% wean but consider every 48 hours rather than every 24.
Adjuncts
  • Phenobarbital — added when the morphine dose exceeds 0.3 mg/kg/dose with scores still above 8, when morphine cannot be weaned for more than 3 consecutive days, or when non-opioid exposure is confirmed. It is also the drug of choice for non-opioid withdrawal. It will not help the gastrointestinal symptoms. Maintenance 5 mg/kg/day divided every 12 hours; levels of 20–30 mcg/mL are effective. Wean only after 3 days of scores below 8, then by 10% every 24 hours or 20% every 48 hours until stopped.
  • Clonidine — 0.5–1.5 mcg/kg orally every 4–6 hours initially, increased over 1–2 days to a target of 3–5 mcg/kg/day divided every 4–6 hours, then tapered by 25% of the total daily dose every other day. Monitor blood pressure — it causes hypotension in use and rebound hypertension on withdrawal.
How long to watch, and what the ESC data show
  • Minimum observation for an asymptomatic at-risk infant (AAP, whatever the scoring system): 72 hours for short-acting opioids, 4 days for buprenorphine, 5 days for methadone. Other substances follow their own half-lives as the neonate metabolizes them.
  • Discharge at 48–72 hours is possible for a narrow group: no maternal use in the last trimester or a history of cocaine or marijuana only; a negative infant urine screen for opioids; maternal HIV, hepatitis B and C and RPR status known with evaluation and follow-up complete; and child protection clearance or an engaged mother with a plan of safe care.
  • Onset and duration by substance (Table 12-6): heroin 24–48 hours, lasting 8–10 days; methadone 48–72 hours, lasting 30 days or more; buprenorphine 36–60 hours, 28 days or more; prescription opioids 36–72 hours, 10–30 days; SSRIs and tricyclics 24–48 hours, 2–6 days; methamphetamines 24 hours, 7–10 days.
  • What Eat-Sleep-Console achieved: Grossman (287 infants) — average stay fell from 22 to 6 days with morphine use down over 80%; Wachman (240 infants) — pharmacological treatment down 47%, adjunct use down 31%, stay 6 days shorter; and a multicentre stepped-wedge cluster-randomized trial confirmed shorter stay and less medication without an increase in specified short-term adverse outcomes (strong recommendation, moderate-quality evidence). Assessment is done by asking the caregiver how the baby ate, slept and consoled — the infant is not moved, undressed or examined for it. Up to 3 as-needed morphine doses before standing doses, and an infant rooming in moves to a level 2 area for 3–4 hours of monitoring after any dose.
  • Toxicology: meconium with the first stool is first-line — it reflects exposure after 20 weeks, is more sensitive than urine, results in a few days, needs a large volume free of urine, and may not reflect recent abstinence. Urine (15–20 mL) reflects only the previous 48 hours but returns quickly — read any positive against maternal prescription and over-the-counter drugs and anything given in labour, such as IV or neuraxial fentanyl, which cause false positives.
  • Co-exposure raises the risk of needing pharmacotherapy by about 30% with one additional substance and 50% with two or more.
  • Feeding: caloric needs may reach 150–250 cal/kg/day; frequent small volumes of 22–24 cal/oz feeds every 2–3 hours reduce hunger and improve growth.
  • Discharge: an infant treated with medication must be observed 48 hours off it, with a primary care appointment secured — ideally within 72 hours — and a warm handover. Early intervention referral is recommended for every substance-exposed infant, with full neurodevelopmental evaluation for those who needed treatment.
⚠ Verify

Agent choice, starting doses, titration, adjuncts, and weaning schedules must follow the Neonatal Formulary and local policy. Continue non-pharmacological care throughout. Flagged for expert review.

9. Breastfeeding

Support Where Appropriate
  • Breastfeeding is encouraged for mothers on stable opioid-agonist treatment (e.g., methadone/buprenorphine) and reduces withdrawal severity and the need for pharmacological treatment.
  • Contraindications include ongoing illicit substance use, certain infections (e.g., HIV per local policy), or specific medications — assess individually.
  • Support the mother compassionately and provide lactation help.

10. Monitoring & Discharge

ItemDetail
ESC functionOngoing — eat/sleep/console; escalate or wean accordingly.
Weight/hydrationEnsure adequate feeding and weight gain.
Observation periodAppropriate to the substance's half-life before discharge.
Family & safeguardingSocial support, safeguarding assessment, and follow-up arranged.
Neurodevelopmental follow-upArrange as indicated.

11. Precautions

Safety Cautions
  • Optimize non-pharmacological care before starting medication; keep mother and baby together.
  • Do not attribute all signs to withdrawal — exclude sepsis, hypoglycemia, and other illness.
  • Verify opioid/adjunct doses; monitor for over-sedation/respiratory depression; wean gradually.
  • Assess breastfeeding suitability individually; support the mother non-judgmentally.
  • Arrange safeguarding, social support, and follow-up before discharge.

12. Escalation & Family Support

Family-Centered Communication
  • "Your baby may be unsettled as they adjust after birth. The best medicine is you — staying together, feeding, holding, and keeping things calm and quiet."
  • "We only add medication if your baby can't feed, sleep, or settle despite this care, and we reduce it slowly. We're here to support you, not to judge."

13. Key Pearls

High-Value Clinical Pearls
  • Non-pharmacological, function-based care (Eat, Sleep, Console) is first-line and reduces medication use and length of stay.
  • Keep mother and baby together (rooming-in); maximize consoling and responsive feeding.
  • Support breastfeeding for mothers on stable opioid-agonist treatment.
  • Start oral morphine only when the infant can't eat/sleep/console despite optimized care; wean gradually.
  • Exclude sepsis/hypoglycemia mimicking withdrawal.
  • Provide compassionate, non-judgmental family and safeguarding support.

14. Common Mistakes to Avoid

MistakeWhy it harmsBetter practice
Score-driven early medication.More opioid use, longer stay.Function-based ESC; optimize non-pharm care.
Separating mother and baby.Less consoling, worse outcomes.Room-in; maximize parental presence.
Discouraging breastfeeding reflexively.Loses a protective factor.Support if on stable agonist treatment.
Blaming/judging the family.Disengagement.Compassionate, non-judgmental care.
Missing concurrent illness.Untreated sepsis/hypoglycemia.Exclude mimics.

15. Board-Style High-Yield Summary

Key Takeaways
  • NAS/NOWS: withdrawal from in-utero opioid (± other substance) exposure; CNS/GI/autonomic signs.
  • Function-based Eat-Sleep-Console care is first-line and reduces medication and length of stay.
  • Keep mother and baby together (rooming-in); optimize non-pharmacological measures; support breastfeeding when appropriate.
  • Pharmacological treatment (usually oral morphine ± adjunct) only when the infant can't eat/sleep/console despite optimized care; wean gradually.
  • Exclude sepsis/hypoglycemia mimics; observe per the substance half-life before discharge.
  • Provide compassionate family, safeguarding, and follow-up support.

16. References

Back to Clinical Guideline Hubs